FCM
ALNY icon

Fieldview Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fieldview Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
+5,275
New +$1.8M 0.51% 38
2025
Q4 		– Sell
-12,658
Closed -$5.77M – 480
2025
Q3 		$5.77M Buy
+12,658
New +$5.15M 0.94% 7

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fieldview Capital Management's ALNY Position: Q1 2026 in Review

Fieldview Capital Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 5,275 shares worth $1.75M. The stake represents 0.51% of the portfolio and ranks #38 among its holdings. This is a return to the name: Fieldview Capital Management previously reported a position in ALNY as recently as Q3 2025.

Fieldview Capital Management first reported a position in ALNY in Q3 2025 and has held it in 2 quarters since. The position peaked at $5.77M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Fieldview Capital Management held 5,275 shares of Alnylam Pharmaceuticals worth $1.75M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Fieldview Capital Management position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.51% of Fieldview Capital Management's portfolio in Q1 2026, its #38 holding.
  • Fieldview Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Fieldview Capital Management's Alnylam Pharmaceuticals position peaked at $5.77M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.